nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—TNF—schizophrenia	0.404	0.577	CbGaD
Thalidomide—CYP1A2—schizophrenia	0.296	0.423	CbGaD
Thalidomide—CYP2C19—urine—schizophrenia	0.00374	0.0401	CbGeAlD
Thalidomide—TNF—blood—schizophrenia	0.00372	0.0398	CbGeAlD
Thalidomide—NFKB1—forebrain—schizophrenia	0.00317	0.034	CbGeAlD
Thalidomide—CYP1A2—urine—schizophrenia	0.00305	0.0327	CbGeAlD
Thalidomide—NFKB1—telencephalon—schizophrenia	0.00291	0.0312	CbGeAlD
Thalidomide—CYP2C9—urine—schizophrenia	0.0029	0.0311	CbGeAlD
Thalidomide—CYP2E1—urine—schizophrenia	0.00275	0.0294	CbGeAlD
Thalidomide—CRBN—forebrain—schizophrenia	0.00266	0.0285	CbGeAlD
Thalidomide—CRBN—telencephalon—schizophrenia	0.00244	0.0262	CbGeAlD
Thalidomide—NFKB1—gonad—schizophrenia	0.00243	0.0261	CbGeAlD
Thalidomide—FGFR2—forebrain—schizophrenia	0.00238	0.0255	CbGeAlD
Thalidomide—FGFR2—telencephalon—schizophrenia	0.00219	0.0235	CbGeAlD
Thalidomide—NFKB1—blood—schizophrenia	0.00212	0.0227	CbGeAlD
Thalidomide—CRBN—gonad—schizophrenia	0.00204	0.0218	CbGeAlD
Thalidomide—Pomalidomide—TNF—schizophrenia	0.00201	0.287	CrCbGaD
Thalidomide—CYP2C19—blood plasma—schizophrenia	0.00195	0.0209	CbGeAlD
Thalidomide—NFKB1—endocrine gland—schizophrenia	0.00184	0.0197	CbGeAlD
Thalidomide—CRBN—blood—schizophrenia	0.00178	0.019	CbGeAlD
Thalidomide—CRBN—midbrain—schizophrenia	0.00175	0.0188	CbGeAlD
Thalidomide—NFKB1—nervous system—schizophrenia	0.00172	0.0184	CbGeAlD
Thalidomide—NFKB1—central nervous system—schizophrenia	0.00166	0.0178	CbGeAlD
Thalidomide—NFKB1—cerebellum—schizophrenia	0.00162	0.0174	CbGeAlD
Thalidomide—CYP1A2—blood plasma—schizophrenia	0.00159	0.0171	CbGeAlD
Thalidomide—FGFR2—blood—schizophrenia	0.00159	0.0171	CbGeAlD
Thalidomide—CRBN—endocrine gland—schizophrenia	0.00154	0.0165	CbGeAlD
Thalidomide—CYP3A5—blood plasma—schizophrenia	0.00154	0.0165	CbGeAlD
Thalidomide—CYP2C9—blood plasma—schizophrenia	0.00151	0.0162	CbGeAlD
Thalidomide—Pomalidomide—CYP1A2—schizophrenia	0.00147	0.21	CrCbGaD
Thalidomide—CRBN—nervous system—schizophrenia	0.00144	0.0155	CbGeAlD
Thalidomide—CYP2E1—blood plasma—schizophrenia	0.00143	0.0154	CbGeAlD
Thalidomide—CRBN—central nervous system—schizophrenia	0.00139	0.0149	CbGeAlD
Thalidomide—PTGS1—blood plasma—schizophrenia	0.00138	0.0148	CbGeAlD
Thalidomide—FGFR2—endocrine gland—schizophrenia	0.00138	0.0148	CbGeAlD
Thalidomide—CRBN—cerebellum—schizophrenia	0.00136	0.0145	CbGeAlD
Thalidomide—PTGS2—blood plasma—schizophrenia	0.00132	0.0141	CbGeAlD
Thalidomide—NFKB1—brain—schizophrenia	0.00131	0.0141	CbGeAlD
Thalidomide—FGFR2—nervous system—schizophrenia	0.00129	0.0138	CbGeAlD
Thalidomide—FGFR2—central nervous system—schizophrenia	0.00124	0.0133	CbGeAlD
Thalidomide—FGFR2—cerebellum—schizophrenia	0.00122	0.013	CbGeAlD
Thalidomide—Menadione—MTHFR—schizophrenia	0.00117	0.167	CrCbGaD
Thalidomide—CRBN—brain—schizophrenia	0.0011	0.0118	CbGeAlD
Thalidomide—FGFR2—brain—schizophrenia	0.000987	0.0106	CbGeAlD
Thalidomide—Lenalidomide—ABCB1—schizophrenia	0.000874	0.125	CrCbGaD
Thalidomide—Pomalidomide—ABCB1—schizophrenia	0.000813	0.116	CrCbGaD
Thalidomide—PTGS1—forebrain—schizophrenia	0.000757	0.00811	CbGeAlD
Thalidomide—PTGS2—forebrain—schizophrenia	0.000723	0.00775	CbGeAlD
Thalidomide—CYP2E1—telencephalon—schizophrenia	0.000722	0.00774	CbGeAlD
Thalidomide—CYP2C19—blood—schizophrenia	0.000715	0.00766	CbGeAlD
Thalidomide—PTGS1—telencephalon—schizophrenia	0.000696	0.00746	CbGeAlD
Thalidomide—Menadione—CYP1A2—schizophrenia	0.000677	0.0964	CrCbGaD
Thalidomide—PTGS2—telencephalon—schizophrenia	0.000665	0.00713	CbGeAlD
Thalidomide—CYP2C19—endocrine gland—schizophrenia	0.00062	0.00665	CbGeAlD
Thalidomide—CYP1A2—blood—schizophrenia	0.000584	0.00626	CbGeAlD
Thalidomide—CYP1A1—blood—schizophrenia	0.000576	0.00617	CbGeAlD
Thalidomide—CYP3A5—blood—schizophrenia	0.000563	0.00604	CbGeAlD
Thalidomide—CYP2C9—blood—schizophrenia	0.000554	0.00594	CbGeAlD
Thalidomide—CYP2E1—blood—schizophrenia	0.000525	0.00563	CbGeAlD
Thalidomide—CYP1A2—endocrine gland—schizophrenia	0.000506	0.00543	CbGeAlD
Thalidomide—PTGS1—blood—schizophrenia	0.000506	0.00542	CbGeAlD
Thalidomide—CYP1A1—endocrine gland—schizophrenia	0.0005	0.00535	CbGeAlD
Thalidomide—CYP3A5—endocrine gland—schizophrenia	0.000488	0.00524	CbGeAlD
Thalidomide—PTGS2—blood—schizophrenia	0.000484	0.00518	CbGeAlD
Thalidomide—CYP2C9—endocrine gland—schizophrenia	0.000481	0.00515	CbGeAlD
Thalidomide—PTGS2—midbrain—schizophrenia	0.000478	0.00512	CbGeAlD
Thalidomide—CYP1A1—nervous system—schizophrenia	0.000468	0.00501	CbGeAlD
Thalidomide—CYP2E1—endocrine gland—schizophrenia	0.000456	0.00488	CbGeAlD
Thalidomide—CYP1A1—central nervous system—schizophrenia	0.00045	0.00482	CbGeAlD
Thalidomide—PTGS1—endocrine gland—schizophrenia	0.000439	0.0047	CbGeAlD
Thalidomide—CYP2E1—nervous system—schizophrenia	0.000426	0.00457	CbGeAlD
Thalidomide—PTGS2—endocrine gland—schizophrenia	0.000419	0.0045	CbGeAlD
Thalidomide—PTGS1—nervous system—schizophrenia	0.000411	0.0044	CbGeAlD
Thalidomide—CYP2E1—central nervous system—schizophrenia	0.00041	0.0044	CbGeAlD
Thalidomide—CYP2E1—cerebellum—schizophrenia	0.000401	0.0043	CbGeAlD
Thalidomide—PTGS1—central nervous system—schizophrenia	0.000395	0.00424	CbGeAlD
Thalidomide—PTGS2—nervous system—schizophrenia	0.000393	0.00421	CbGeAlD
Thalidomide—PTGS2—central nervous system—schizophrenia	0.000378	0.00405	CbGeAlD
Thalidomide—PTGS2—cerebellum—schizophrenia	0.000369	0.00396	CbGeAlD
Thalidomide—CYP1A1—brain—schizophrenia	0.000357	0.00383	CbGeAlD
Thalidomide—CYP2E1—brain—schizophrenia	0.000326	0.00349	CbGeAlD
Thalidomide—PTGS1—brain—schizophrenia	0.000314	0.00337	CbGeAlD
Thalidomide—PTGS2—brain—schizophrenia	0.0003	0.00322	CbGeAlD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—schizophrenia	1.58e-05	7.9e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ERBB4—schizophrenia	1.57e-05	7.84e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NDUFV2—schizophrenia	1.56e-05	7.79e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—DPYD—schizophrenia	1.55e-05	7.77e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PLA2G4A—schizophrenia	1.55e-05	7.77e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP26B1—schizophrenia	1.55e-05	7.75e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GAPDH—schizophrenia	1.54e-05	7.7e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GAPDH—schizophrenia	1.54e-05	7.69e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CLOCK—schizophrenia	1.53e-05	7.63e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NRG1—schizophrenia	1.52e-05	7.63e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CLOCK—schizophrenia	1.52e-05	7.62e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TPH1—schizophrenia	1.51e-05	7.57e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GCLM—schizophrenia	1.51e-05	7.57e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MEF2C—schizophrenia	1.51e-05	7.56e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SNAP25—schizophrenia	1.51e-05	7.54e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—GSK3B—schizophrenia	1.5e-05	7.5e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—TPH2—schizophrenia	1.49e-05	7.44e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CACNB2—schizophrenia	1.49e-05	7.44e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CACNB2—schizophrenia	1.48e-05	7.42e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—TPH2—schizophrenia	1.48e-05	7.42e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PLA2G4A—schizophrenia	1.47e-05	7.37e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIP4K2A—schizophrenia	1.46e-05	7.32e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—DPYD—schizophrenia	1.46e-05	7.32e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—YWHAZ—schizophrenia	1.46e-05	7.31e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—DPYD—schizophrenia	1.46e-05	7.3e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GAPDH—schizophrenia	1.45e-05	7.26e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NRG1—schizophrenia	1.45e-05	7.24e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CACNA1C—schizophrenia	1.44e-05	7.23e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CLOCK—schizophrenia	1.44e-05	7.2e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CYP1A2—schizophrenia	1.44e-05	7.2e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—APOE—schizophrenia	1.43e-05	7.18e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MEF2C—schizophrenia	1.43e-05	7.17e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ERBB3—schizophrenia	1.43e-05	7.15e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G4A—schizophrenia	1.43e-05	7.14e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PRKD1—schizophrenia	1.42e-05	7.12e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—APOA1—schizophrenia	1.42e-05	7.1e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—TH—schizophrenia	1.42e-05	7.09e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3C2A—schizophrenia	1.41e-05	7.04e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CACNB2—schizophrenia	1.4e-05	7.01e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—TPH2—schizophrenia	1.4e-05	7.01e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—YWHAZ—schizophrenia	1.38e-05	6.93e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GCLM—schizophrenia	1.38e-05	6.91e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TPH1—schizophrenia	1.38e-05	6.91e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—DPYD—schizophrenia	1.38e-05	6.9e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HTR2A—schizophrenia	1.37e-05	6.88e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CACNA1C—schizophrenia	1.36e-05	6.8e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CACNA1C—schizophrenia	1.36e-05	6.79e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ERBB3—schizophrenia	1.35e-05	6.78e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HSPA1A—schizophrenia	1.35e-05	6.77e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS1—schizophrenia	1.34e-05	6.72e-05	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—schizophrenia	1.33e-05	6.67e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3C2A—schizophrenia	1.32e-05	6.63e-05	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—AKT1—schizophrenia	1.32e-05	6.62e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP26B1—schizophrenia	1.32e-05	6.62e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3C2A—schizophrenia	1.32e-05	6.62e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HTR2A—schizophrenia	1.3e-05	6.53e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—schizophrenia	1.3e-05	6.51e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PRKD1—schizophrenia	1.3e-05	6.49e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CACNA1C—schizophrenia	1.28e-05	6.41e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—APOE—schizophrenia	1.28e-05	6.39e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—APOA1—schizophrenia	1.26e-05	6.32e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—SNAP25—schizophrenia	1.26e-05	6.32e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP2D6—schizophrenia	1.26e-05	6.32e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL1B—schizophrenia	1.26e-05	6.3e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3C2A—schizophrenia	1.25e-05	6.25e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PRL—schizophrenia	1.25e-05	6.24e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ESR1—schizophrenia	1.22e-05	6.1e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—APOE—schizophrenia	1.21e-05	6.07e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—COMT—schizophrenia	1.2e-05	6.03e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GSTP1—schizophrenia	1.2e-05	6e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—APOA1—schizophrenia	1.2e-05	6e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—MAOA—schizophrenia	1.2e-05	5.99e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL1B—schizophrenia	1.2e-05	5.98e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP2D6—schizophrenia	1.19e-05	5.95e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—SNAP25—schizophrenia	1.19e-05	5.95e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GAPDH—schizophrenia	1.19e-05	5.94e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—SNAP25—schizophrenia	1.19e-05	5.93e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP2D6—schizophrenia	1.19e-05	5.93e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TPH1—schizophrenia	1.18e-05	5.9e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GCLM—schizophrenia	1.18e-05	5.9e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CLOCK—schizophrenia	1.18e-05	5.89e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—schizophrenia	1.17e-05	5.88e-05	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—AKT1—schizophrenia	1.17e-05	5.85e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—APOA1—schizophrenia	1.16e-05	5.81e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—EP300—schizophrenia	1.16e-05	5.81e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ESR1—schizophrenia	1.16e-05	5.79e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TPH2—schizophrenia	1.15e-05	5.74e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CACNB2—schizophrenia	1.15e-05	5.74e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP1A2—schizophrenia	1.14e-05	5.71e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ABCB1—schizophrenia	1.14e-05	5.68e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—DPYD—schizophrenia	1.13e-05	5.65e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—EP300—schizophrenia	1.13e-05	5.64e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—TH—schizophrenia	1.12e-05	5.63e-05	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—AKT1—schizophrenia	1.12e-05	5.61e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYP2D6—schizophrenia	1.12e-05	5.61e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—SNAP25—schizophrenia	1.12e-05	5.61e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—schizophrenia	1.11e-05	5.56e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ERBB4—schizophrenia	1.11e-05	5.56e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PRKD1—schizophrenia	1.11e-05	5.55e-05	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—AKT1—schizophrenia	1.11e-05	5.55e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—GSK3B—schizophrenia	1.11e-05	5.54e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GSTM1—schizophrenia	1.1e-05	5.52e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PLA2G4A—schizophrenia	1.1e-05	5.52e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GAPDH—schizophrenia	1.08e-05	5.42e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP1A2—schizophrenia	1.07e-05	5.38e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CLOCK—schizophrenia	1.07e-05	5.37e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP1A2—schizophrenia	1.07e-05	5.37e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—schizophrenia	1.07e-05	5.36e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—EP300—schizophrenia	1.07e-05	5.35e-05	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—AKT1—schizophrenia	1.06e-05	5.33e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—TH—schizophrenia	1.06e-05	5.3e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—schizophrenia	1.06e-05	5.3e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—TH—schizophrenia	1.06e-05	5.29e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—GSK3B—schizophrenia	1.05e-05	5.25e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CACNA1C—schizophrenia	1.05e-05	5.25e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CACNB2—schizophrenia	1.05e-05	5.23e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TPH2—schizophrenia	1.05e-05	5.23e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—DPYD—schizophrenia	1.03e-05	5.15e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NRG1—schizophrenia	1.03e-05	5.13e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3C2A—schizophrenia	1.02e-05	5.12e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYP1A2—schizophrenia	1.01e-05	5.07e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—AKT1—schizophrenia	1.01e-05	5.04e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—TH—schizophrenia	9.98e-06	5e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—EP300—schizophrenia	9.86e-06	4.94e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—YWHAZ—schizophrenia	9.82e-06	4.92e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—MTHFR—schizophrenia	9.74e-06	4.88e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ERBB3—schizophrenia	9.61e-06	4.81e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—COMT—schizophrenia	9.57e-06	4.79e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CACNA1C—schizophrenia	9.56e-06	4.79e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GSTP1—schizophrenia	9.52e-06	4.77e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—MAOA—schizophrenia	9.5e-06	4.75e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3C2A—schizophrenia	9.32e-06	4.66e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GAPDH—schizophrenia	9.25e-06	4.63e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MTHFR—schizophrenia	9.23e-06	4.62e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—EP300—schizophrenia	9.21e-06	4.61e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CLOCK—schizophrenia	9.17e-06	4.59e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP2D6—schizophrenia	9.17e-06	4.59e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—SNAP25—schizophrenia	9.17e-06	4.59e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—schizophrenia	9.15e-06	4.58e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—APOE—schizophrenia	9.07e-06	4.54e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—schizophrenia	9.04e-06	4.53e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ABCB1—schizophrenia	9.01e-06	4.51e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—COMT—schizophrenia	9e-06	4.51e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—COMT—schizophrenia	8.99e-06	4.5e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—APOA1—schizophrenia	8.96e-06	4.49e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GSTP1—schizophrenia	8.96e-06	4.49e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GSTP1—schizophrenia	8.94e-06	4.48e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—MAOA—schizophrenia	8.94e-06	4.48e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TPH2—schizophrenia	8.93e-06	4.47e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CACNB2—schizophrenia	8.93e-06	4.47e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—MAOA—schizophrenia	8.92e-06	4.47e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—DPYD—schizophrenia	8.79e-06	4.4e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PLA2G4A—schizophrenia	8.75e-06	4.38e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GSTM1—schizophrenia	8.75e-06	4.38e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APOE—schizophrenia	8.6e-06	4.3e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APOA1—schizophrenia	8.5e-06	4.25e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—COMT—schizophrenia	8.49e-06	4.25e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ABCB1—schizophrenia	8.48e-06	4.25e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ABCB1—schizophrenia	8.47e-06	4.24e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GSTP1—schizophrenia	8.45e-06	4.23e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—MAOA—schizophrenia	8.43e-06	4.22e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP2D6—schizophrenia	8.36e-06	4.18e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SNAP25—schizophrenia	8.36e-06	4.18e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP1A2—schizophrenia	8.29e-06	4.15e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PLA2G4A—schizophrenia	8.24e-06	4.12e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GSTM1—schizophrenia	8.24e-06	4.12e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GSTM1—schizophrenia	8.22e-06	4.11e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PLA2G4A—schizophrenia	8.22e-06	4.11e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—EP300—schizophrenia	8.17e-06	4.09e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CACNA1C—schizophrenia	8.17e-06	4.09e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TH—schizophrenia	8.17e-06	4.09e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ABCB1—schizophrenia	8e-06	4e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3C2A—schizophrenia	7.96e-06	3.99e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GSTM1—schizophrenia	7.76e-06	3.89e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PLA2G4A—schizophrenia	7.76e-06	3.89e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—MTHFR—schizophrenia	7.73e-06	3.87e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP1A2—schizophrenia	7.56e-06	3.78e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TH—schizophrenia	7.45e-06	3.73e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—GSK3B—schizophrenia	7.44e-06	3.73e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EP300—schizophrenia	7.28e-06	3.64e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—MTHFR—schizophrenia	7.28e-06	3.64e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—MTHFR—schizophrenia	7.26e-06	3.64e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—APOE—schizophrenia	7.2e-06	3.6e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SNAP25—schizophrenia	7.14e-06	3.58e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP2D6—schizophrenia	7.14e-06	3.58e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—APOA1—schizophrenia	7.12e-06	3.56e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—COMT—schizophrenia	6.95e-06	3.48e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTP1—schizophrenia	6.91e-06	3.46e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EP300—schizophrenia	6.91e-06	3.46e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MAOA—schizophrenia	6.9e-06	3.45e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—MTHFR—schizophrenia	6.86e-06	3.43e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—AKT1—schizophrenia	6.8e-06	3.41e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOE—schizophrenia	6.78e-06	3.39e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOE—schizophrenia	6.76e-06	3.38e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOA1—schizophrenia	6.7e-06	3.35e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—schizophrenia	6.69e-06	3.35e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOA1—schizophrenia	6.68e-06	3.35e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ABCB1—schizophrenia	6.55e-06	3.28e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—AKT1—schizophrenia	6.46e-06	3.23e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOE—schizophrenia	6.39e-06	3.2e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TH—schizophrenia	6.37e-06	3.19e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PLA2G4A—schizophrenia	6.35e-06	3.18e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTM1—schizophrenia	6.35e-06	3.18e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—COMT—schizophrenia	6.33e-06	3.17e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOA1—schizophrenia	6.32e-06	3.16e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTP1—schizophrenia	6.3e-06	3.16e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MAOA—schizophrenia	6.29e-06	3.15e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—schizophrenia	6.1e-06	3.05e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ABCB1—schizophrenia	5.97e-06	2.99e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—AKT1—schizophrenia	5.96e-06	2.98e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PLA2G4A—schizophrenia	5.79e-06	2.9e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTM1—schizophrenia	5.79e-06	2.9e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MTHFR—schizophrenia	5.62e-06	2.81e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—COMT—schizophrenia	5.41e-06	2.71e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTP1—schizophrenia	5.39e-06	2.7e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MAOA—schizophrenia	5.37e-06	2.69e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOE—schizophrenia	5.23e-06	2.62e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—schizophrenia	5.21e-06	2.61e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—schizophrenia	5.21e-06	2.61e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOA1—schizophrenia	5.17e-06	2.59e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—EP300—schizophrenia	5.17e-06	2.59e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MTHFR—schizophrenia	5.12e-06	2.56e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ABCB1—schizophrenia	5.1e-06	2.55e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTM1—schizophrenia	4.95e-06	2.48e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PLA2G4A—schizophrenia	4.95e-06	2.48e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—schizophrenia	4.94e-06	2.47e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EP300—schizophrenia	4.9e-06	2.45e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOE—schizophrenia	4.77e-06	2.39e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOA1—schizophrenia	4.71e-06	2.36e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AKT1—schizophrenia	4.4e-06	2.2e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MTHFR—schizophrenia	4.38e-06	2.19e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AKT1—schizophrenia	4.17e-06	2.09e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—EP300—schizophrenia	4.1e-06	2.05e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOE—schizophrenia	4.07e-06	2.04e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOA1—schizophrenia	4.03e-06	2.02e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—EP300—schizophrenia	3.86e-06	1.93e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—EP300—schizophrenia	3.85e-06	1.93e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—EP300—schizophrenia	3.64e-06	1.82e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AKT1—schizophrenia	3.12e-06	1.56e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—EP300—schizophrenia	2.98e-06	1.49e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—AKT1—schizophrenia	2.96e-06	1.48e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—EP300—schizophrenia	2.72e-06	1.36e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AKT1—schizophrenia	2.48e-06	1.24e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AKT1—schizophrenia	2.33e-06	1.17e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AKT1—schizophrenia	2.33e-06	1.17e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—EP300—schizophrenia	2.32e-06	1.16e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AKT1—schizophrenia	2.2e-06	1.1e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AKT1—schizophrenia	1.8e-06	9.01e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AKT1—schizophrenia	1.64e-06	8.22e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AKT1—schizophrenia	1.4e-06	7.02e-06	CbGpPWpGaD
